X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Is a Favorite Amongst Institutional Investors Who Own 51%
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
X4 Pharmaceuticals Unveils Corporate Presentation for Investors
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
10-Q: Q2 2024 Earnings Report
X4 Pharmaceuticals GAAP EPS of $0.45 Beats by $0.46
Express News | X4 Pharmaceuticals Inc: Believes It Has Sufficient Funds to Support Company Operations Into Late 2025
Press Release: X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
X4 Pharmaceuticals 2Q EPS 45c >XFOR
Express News | X4 Pharmaceuticals Q2 EPS USD 0.45 Vs. IBES Estimate USD 0.01
Express News | X4 Pharmaceuticals Q2 Net Income USD 90.833 Million
Express News | X4 Pharmaceuticals Q2 Income From Operations USD 71.103 Million
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
X4 Pharmaceuticals Q2 2024 Earnings Preview
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
X4 Pharmaceuticals Updates Corporate Presentation for Investors
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $5 Price Target
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Swayampakula Ramakanth maintains $X4 Pharmaceuticals(XFOR.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rat